L&T Technology Services Launches Second Annual Digital Engineering Awards, in collaboration with ISG and CNBC TV-18
15.9.2023 11:30:00 EEST | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global digital engineering and R&D company, today announced the launch of the second-annual Digital Engineering Awards, in association with Information Services Group (ISG), a leading global technology research and advisory firm, and business news channel CNBC TV-18 in India.
The Digital Engineering Awards recognize and celebrate business and technology trailblazers who are crafting a smarter and more sustainable world through transformative ideas that leverage digital engineering.
Enterprises and their service providers are invited to submit nominations through October 5, with winners announced during a gala awards celebration on December 6 in Dallas, Tex., U.S.A. Enterprise award winners, selected by a global panel of industry experts, including representatives of ISG, will be named in nine categories – five team awards and four individual awards:
Engineering the Change Team Awards
- Digital Transformation of the Year
- Top Sustainability Initiative
- Digital Engineering Program of the Year
- Engineering Product of the Year
- Value Realization
Engineering at Heart Individual Awards
- Distinguished Digital Engineer
- Digital Engineer of the Year
- Woman Engineer of the Year
- Innovator of the Year
The inaugural Digital Engineering Awards gala was held last year in Jersey City, N.J., United States, with 120 nominees, including over 70 industry-leading global enterprises, in attendance. Winners, both individual engineers and teams, included representatives from Airbus, American Honda Motor Co., Inc./ Honda Marine, Chevron, ExxonMobil, GE Healthcare, Intel Corporation, Microsoft, Rolls-Royce, and Qualcomm Technologies.
Remarking on the occasion, Mr. Amit Chadha, CEO and Managing Director at L&T Technology Services said, "We take immense pride in having witnessed the tremendous success of the maiden Digital Engineering Awards, which celebrated disruptive innovations across a broad spectrum of deep technologies, spanning automotive, aerospace, industrial products, telecom, plant engineering, and medical devices. As we persist in our unwavering commitment to engineering research and development, aiming to shape a future enabled by engineering marvels, we are eager to extend our endeavors in spotlighting extraordinary innovation and leadership that spearheads transformation towards a sustainable, digitally empowered tomorrow."
“Digital engineering is the fabric that connects all facets of the digital world and makes future innovations possible,” said Michael P. Connors, Chairman and CEO of ISG. “Following the great success of the inaugural Digital Engineering Awards, we are delighted once again to collaborate with L&T Technology Services and CNBC-TV18 to recognize the outstanding work of individuals and teams whose groundbreaking innovations will shape the digital landscape for years to come.”
“The Digital Engineering Awards have a key role to play in celebrating the new-age digital solutions that are driving immense growth in the ER&D sector. Our role as media partner with L&T Technology Services aligns perfectly with the long-standing objective of our brands – CNBC-TV18 and Moneycontrol – to educate audiences about innovations and developments in the worlds of technology and business,” said S. Shivakumar: President, News18 Studios.
About the Digital Engineering Awards
The Digital Engineering Awards bring together industry leaders to recognize outstanding achievements in the R&D domain, and to help global organizations give shape to their transformative ideas. The Awards are produced by L&T Technology Services in association with ISG, with CNBC TV18 as a media partner. For more about the Awards, visit this website (www.digitalengineeringawards.com) or contact us at info@digitalengineeringawards.com
About Network18
Network18 Media & Investments Limited is a major Indian media conglomerate owned by Reliance Industries. The company operates a wide array of channels spanning news, entertainment, and digital content. Its portfolio includes CNBC-TV18, CNBC-AWAAZ, CNBC-Bajar, CNN-NEWS18, News18 India, and News18 regional news channels across languages and markets.
About ISG
ISG (Information Services Group) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 23,300 employees spread across 22 global design centers, 28 global sales offices and 102 innovation labs as of June 30, 2023. For more information, please visit https://www.LTTS.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230914274834/en/
Contact information
Aniruddha Basu
L&T Technology Services Limited
E: Aniruddha.Basu@Ltts.com
Anindita Sarkar
L&T Technology Services Limited
E: Anindita.Sarkar@Ltts.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom